幽门螺杆菌感染耐药的中西医治疗对策

贾晓芬; 叶晖; 张学智

doi:10.3969/j.issn.1671-038X.2024.04.04

幽门螺杆菌感染耐药的中西医治疗对策

- 北京大学第一医院中医、中西医结合科北京大学中西医结合研究所(北京，100034)
基金项目:
国家中医药管理局中医传承与创新“百千万”人才工程(岐黄工程)——国家中医药领军人才支撑计划项目-张学智[No: 国中医人教函(2022)6号]; 中央高水平医院临床科研业务费资助(北京大学第一医院科研种子基金项目)(No: 2024SF87); 中央高水平医院临床科研业务项目(北京大学第一医院国内多中心临床研究专项)(No: 2022CR64); 首都卫生发展科研专项自主创新项目(No: 首发2022-2-4077)

详细信息

通讯作者: 张学智, E-mail: zhang.xuezhi@263.net

^Δ审校者

中图分类号: R256.3

收稿日期: 2024-01-20

刊出日期: 2024-04-15

Countermeasures of Integrated Traditional Chinese and Western Medicine for drug-resistant Helicobacter pylori

- Department of Integrated Traditional Chinese and Western Medicine, Peking University First Hospital, Institute of Integrated Traditional Chinese and Western Medicine, Peking University, Beijing, 100034, China

More Information

Corresponding author: ZHANG Xuezhi, E-mail: zhang.xuezhi@263.net

Received Date: 20 January 2024

Publish Date: 15 April 2024

摘要

摘要: 幽门螺杆菌(Helicobacter pylori，HP)感染是胃癌发生的主要危险因素，根除HP可以有效降低胃癌的发生率和病死率。然而，大规模的HP根除治疗和抗生素的不规范使用导致HP对多种抗生素的耐药率逐渐升高，成为导致HP根除失败的主要原因。中西医在对耐药HP的治疗中各有优势，二者相结合构成的病证结合个体化诊疗方案有望为耐药HP的治疗提供更为全面、有效的解决方案，为临床治疗提供更多的选择。
- 幽门螺杆菌 /
- 抗生素耐药 /
- 难治性幽门螺杆菌感染 /
- 中医药 /
- 中西医协作
Abstract: Helicobacter pylori(H.pylori) infection is a major risk factor for gastric cancer and eradication of H.pylori can effectively reduce the incidence and mortality of gastric cancer. However, large-scale eradication treatments and irregular use of antibiotics have led to a gradual increase in the antibiotic resistance rate of H.pylori, which is the main reason for the failure of H.pylori eradication. Traditional Chinese Medicine and Western Medicine each have their own advantages in the treatment of drug-resistant H.pylori. The individualized diagnosis and treatment therapy composed of the combination of the two is expected to provide a more comprehensive and effective solution for the treatment of drug-resistant H.pylori, and provide more choices for clinical treatment.
- Helicobacter pylori /
- antibiotic resistance /
- refractory Helicobacter pylori infection /
- Traditional Chinese Medicine /
- cooperation of Traditional Chinese and Western Medicine

HTML全文

参考文献(39)

[1]	Chiang TH, Chang WJ, Chen SL, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands[J]. Gut, 2021, 70(2): 243-250.
[2]	Yan L, Chen Y, Chen F, et al. Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up[J]. Gastroenterology, 2022, 163(1): 154-162.e3. doi: 10.1053/j.gastro.2022.03.039
[3]	Mera RM, Bravo LE, Camargo MC, et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial[J]. Gut, 2018, 67(7): 1239-1246. doi: 10.1136/gutjnl-2016-311685
[4]	Zhong Z, Zhan B, Xu B, et al. Emphasizing the importance of successful eradication of Helicobacter pylori on initial treatment[J]. Am J Cancer Res, 2022, 12(3): 1215-1221.
[5]	Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis[J]. Lancet Infect Dis, 2018, 18(3): 318-327. doi: 10.1016/S1473-3099(17)30753-3
[6]	张学智, 魏玮, 蓝宇. 成人幽门螺杆菌引起的胃炎中西医协作诊疗专家共识(2020, 北京)[J]. 中医杂志, 2020, 61(22): 2016-2024. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202022023.htm
[7]	康影, 刘昊, 董笑一, 等. 茵连和胃颗粒联合四联疗法治疗Hp相关性胃炎的疗效分析[J]. 中国中西医结合消化杂志, 2022, 30(11): 765-768. doi: 10.3969/j.issn.1671-038X.2022.11.02
[8]	Hong TC, El-Omar EM, Kuo YT, et al. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2024, 9(1): 56-67. doi: 10.1016/S2468-1253(23)00281-9
[9]	Zhong Z, Zhang Z, Wang J, et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China[J]. Am J Cancer Res, 2021, 11(10): 5027-5037.
[10]	Kuo CJ, Lee CH, Chang ML, et al. Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection[J]. J Microbiol Immunol Infect, 2021, 54(6): 1184-1187. doi: 10.1016/j.jmii.2021.03.006
[11]	Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance-from biology to clinical implications[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(9): 613-629. doi: 10.1038/s41575-021-00449-x
[12]	Zanotti G, Cendron L. Structural Aspects of Helicobacter pylori Antibiotic Resistance[J]. Adv Exp Med Biol, 2019, 1149: 227-241.
[13]	Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review[J]. Gastroenterology, 2021, 160(5): 1831-1841. doi: 10.1053/j.gastro.2020.11.059
[14]	中华医学会消化病学分会幽门螺杆菌学组. 第六次全国幽门螺杆菌感染处理共识报告(非根除治疗部分)[J]. 中华消化杂志, 2022, 42(5): 289-303. doi: 10.3760/cma.j.cn311367-20220206-00057
[15]	Brennan D, O'Morain C, McNamara D, et al. Molecular Detection of Antibiotic-Resistant Helicobacter pylori[J]. Methods Mol Biol, 2021, 2283: 29-36.
[16]	Fauzia KA, Tuan VP. Rising resistance: antibiotic choices for Helicobacter pylori infection[J]. Lancet Gastroenterol Hepatol, 2024, 9(1): 7-8. doi: 10.1016/S2468-1253(23)00354-0
[17]	中华医学会消化病学分会幽门螺杆菌学组. 2022中国幽门螺杆菌感染治疗指南[J]. 中华消化杂志, 2022, 42(11): 745-756. doi: 10.3760/cma.j.cn311367-20220929-00479
[18]	Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht Ⅵ/Florence consensus report[J]. Gut, 2022: gutjnl-2022-327745.
[19]	Gao CP, Zhou Z, Wang JZ, et al. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis[J]. J Dig Dis, 2016, 17(12): 811-819. doi: 10.1111/1751-2980.12432
[20]	Laine L, DeVault K, Katz P, et al. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial[J]. Gastroenterology, 2023, 164(1): 61-71. doi: 10.1053/j.gastro.2022.09.041
[21]	Gao W, Teng G, Wang C, et al. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China[J]. Helicobacter, 2022, 27(5): e12918. doi: 10.1111/hel.12918
[22]	孟旨毅, 孟宪梅, 张静洁. Hp根除治疗方案研究进展[J]. 中国中西医结合消化杂志, 2022, 30(11): 809-812. doi: 10.3969/j.issn.1671-038X.2022.11.11
[23]	张恩恩, 叶晖, 贾晓芬, 等. 土荆芥提取物在体外对幽门螺杆菌生物膜的作用[J]. 中国中西医结合杂志, 2020, 40(10): 1241-1245. doi: 10.7661/j.cjim.20200904.334
[24]	Jia X, Huang Q, Lin M, et al. Revealing the novel effect of Jinghua Weikang capsule against the antibiotic resistance of Helicobacter pylori[J]. Front Microbiol, 2022, 13: 962354. doi: 10.3389/fmicb.2022.962354
[25]	Li RJ, Qin C, Huang GR, et al. Phillygenin Inhibits Helicobacter pylori by Preventing Biofilm Formation and Inducing ATP Leakage[J]. Front Microbiol, 2022, 13: 863624. doi: 10.3389/fmicb.2022.863624
[26]	Xu YF, Lian DW, Chen YQ, et al. In Vitro and In Vivo Antibacterial Activities of Patchouli Alcohol, a Naturally Occurring Tricyclic Sesquiterpene, against Helicobacter pylori Infection[J]. Antimicrob Agents Chemother, 2017, 61(6): e00122-17.
[27]	Luo P, Huang Y, Hang X, et al. Dihydrotanshinone Ⅰ Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo[J]. Antimicrob Agents Chemother, 2021, 65(3): e01921-20.
[28]	Peng C, Sang S, Shen X, et al. In vitro anti-Helicobacter pylori activity of Syzygium aromaticum and the preliminary mechanism of action[J]. J Ethnopharmacol, 2022, 288: 114995. doi: 10.1016/j.jep.2022.114995
[29]	贾晓芬. 荆花胃康胶丸抗幽门螺杆菌耐药的效应机制研究及对肠道菌群的影响[D]. 北京: 北京大学, 2023.
[30]	Tran Trung H, Truong Thi Huynh H, Nguyen Thi Thuy L, et al. Growth-Inhibiting, Bactericidal, Antibiofilm, and Urease Inhibitory Activities of Hibiscus rosa sinensis L. Flower Constituents toward Antibiotic Sensitive-and Resistant-Strains of Helicobacter pylori[J]. ACS Omega, 2020, 5(32): 20080-20089. doi: 10.1021/acsomega.0c01640
[31]	Vikram A, Jayaprakasha GK, Jesudhasan PR, et al. Suppression of bacterial cell-cell signalling, biofilm formation and type Ⅲsecretion system by citrus flavonoids[J]. J Appl Microbiol, 2010, 109(2): 515-527. doi: 10.1111/j.1365-2672.2010.04677.x
[32]	Shen Y, Zou Y, Chen X, et al. Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori[J]. J Control Release, 2020, 328: 575-586. doi: 10.1016/j.jconrel.2020.09.025
[33]	Huang YQ, Huang GR, Wu MH, et al. Inhibitory effects of emodin, baicalin, schizandrin and berberine on hefA gene: treatment of Helicobacter pylori-induced multidrug resistance[J]. World J Gastroenterol, 2015, 21(14): 4225-4231. doi: 10.3748/wjg.v21.i14.4225
[34]	Zhong Y, Tang L, Deng Q, et al. Unraveling the Novel Effect of Patchouli Alcohol Against the Antibiotic Resistance of Helicobacter pylori[J]. Front Microbiol, 2021, 12: 674560. doi: 10.3389/fmicb.2021.674560
[35]	Krzyzek P, Migdal P, Paluch E, et al. Myricetin as an Antivirulence Compound Interfering with a Morphological Transformation into Coccoid Forms and Potentiating Activity of Antibiotics against Helicobacter pylori[J]. Int J Mol Sci, 2021, 22(5): 2695. doi: 10.3390/ijms22052695
[36]	Krzyzek P, Gosciniak G. Morphology of Helicobacter pylori as a result of peptidoglycan and cytoskeleton rearrangements[J]. Prz Gastroenterol, 2018, 13(3): 182-195.
[37]	Yang Z, Xiong W, Yang R, et al. A day-to-day management model improves patient compliance to treatment for Helicobacter pylori infection: a prospective, randomized controlled study[J]. Gut Pathog, 2023, 15(1): 38. doi: 10.1186/s13099-023-00556-x
[38]	成虹, 胡伏莲, 盛剑秋, 等. 荆花胃康胶丸联合含呋喃唑酮三联或四联疗法补救治疗幽门螺杆菌感染的多中心随机对照研究[J]. 中华医学杂志, 2016, 96(40): 3206-3212. doi: 10.3760/cma.j.issn.0376-2491.2016.40.002
[39]	胡伏莲, 张声生. 全国中西医整合治疗幽门螺杆菌相关"病-证"共识[J]. 胃肠病学和肝病学杂志, 2018, 27(9): 1008-1016. doi: 10.3969/j.issn.1006-5709.2018.09.012